Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl-
paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or
4 mg/kg IV loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w IV, respectively).
However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13
dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this
metabolite was unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study
(H0648g) in which patients were treated concomitantly with Herceptin and paclitaxel and two Phase II
studies in which Herceptin was administered as monotherapy (W016229 and MO16982), in women
with HER2-positive MBC indicates that individual and mean trastuzumab trough serum
concentrations varied within and across studies but there was no clear effect of the concomitant
administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK
data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with
Herceptin, paclitaxel and doxorubicin to trastuzumab PK data in studies where Herceptin was
administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide
or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the
pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC
suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl-
paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or
4 mg/kg IV loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w IV, respectively).
However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13
dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this
metabolite was unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study
(H0648g) in which patients were treated concomitantly with Herceptin and paclitaxel and two Phase II
studies in which Herceptin was administered as monotherapy (W016229 and MO16982), in women
with HER2-positive MBC indicates that individual and mean trastuzumab trough serum
concentrations varied within and across studies but there was no clear effect of the concomitant
administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK
data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with
Herceptin, paclitaxel and doxorubicin to trastuzumab PK data in studies where Herceptin was
administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide
or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the
pharmacokinetics of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage 18fed877413ea053f5f860995d67b670727bcf7873c907cc43f4c456d3102050 · Zeichen 2464–3430 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.